Background
==========

According to the American Cancer Society, approximately 231 840 new cases of invasive breast cancer and 40 290 breast cancer deaths occurred among US women in 2015. Breast cancer is the second leading cause of cancer-related deaths in women \[[@b1-medscimonit-23-1583]\]. The improvements in early diagnosis, surgical techniques, and adjuvant therapies have progressively decreased the mortality of breast cancer in the past 2 decades \[[@b2-medscimonit-23-1583]\]. However, metastatic breast cancer is still incurable and fatal. Breast cancer metastasis is a multistep process associated with cellular motility, basement membrane degradation, epithelial to mesenchymal transition (EMT), and circulating and disseminating tumor cells \[[@b3-medscimonit-23-1583],[@b4-medscimonit-23-1583]\]. EMT was first identified in embryonic development \[[@b5-medscimonit-23-1583]\], and it participates in most cancer metastatic cascades. After EMT, tumor cells subsequently acquire invasiveness, penetrate to the basement membrane, gain access to the blood or lymphatic vascular systems, reach distant secondary sites, and eventually form macroscopic tumors \[[@b6-medscimonit-23-1583]--[@b8-medscimonit-23-1583]\]. Although transplantation models of breast cancer cells provide important mechanistic insights into the metastatic cascade, these models are limited by potential species incompatibilities in growth factor signaling pathways, which obscure the processes that are active in patients \[[@b9-medscimonit-23-1583]\]. In terms of the primary lesion in transplantation models, the tumor cells are not in the same phase as in the EMT process. The transient nature of EMT adds to the complexity of the results and their interpretation. As one of the key components of tumor metastasis, EMT of tumor cells is intimately linked with the tumor microenvironment. Simulation of the special tumor microenvironment is therefore the central premise of EMT research.

A mouse model containing human-derived normal breast tissue was established in our previous study, which allowed human breast cancer cells to proliferate in the human mammary microenvironment and to finally metastasize to distant human tissues \[[@b10-medscimonit-23-1583],[@b11-medscimonit-23-1583]\]. The initial microenvironment significantly influences the behavior of cancer cells. Homogeneous cells avoid interference by other cell types, and instead highlight changes in cells initiated by the microenvironment. MDA-MB-231br was obtained from the invasive front of a tumor in transplanted normal human breast tissue, and metastasized preferentially to human tissues when proliferating in the normal human mammary microenvironment \[[@b10-medscimonit-23-1583]\]. Importantly, the invasive MDA-MB-231br cells participate in the EMT process. In a primary culture, MDA-MB-231br displayed EMT-like changes and was more invasive compared to parent MDA-MB-231 cells.

Ezrin, a member of the ezrin-radixin-moesin (ERM) family, acts as a crosslinker between membranes and the actin cytoskeleton. Ezrin also regulates a variety of cellular activities, such as actin cytoskeleton regulation, cellular morphology, cellular adherence, and modulation of intracellular signaling pathways \[[@b12-medscimonit-23-1583]--[@b14-medscimonit-23-1583]\]. It is expressed in most normal and cancer tissues, and is expressed at significantly higher levels in cancers of mesenchymal origin (sarcomas) \[[@b15-medscimonit-23-1583],[@b16-medscimonit-23-1583]\]. The expression of cytoplasmic ezrin incrementally increases during the development of benign lesions into malignant breast tumors \[[@b17-medscimonit-23-1583],[@b18-medscimonit-23-1583]\]. Although substantial evidence has linked ezrin to metastatic behavior in breast cancer, it is still unknown whether EMT is involved. Cortactin, a protein widespread in cellular locomotive organs (e.g., lamellipodia and invasive pseudopodia), regulates branched actin assembly, cell-cell adhesion, membrane trafficking, and ECM degradation \[[@b19-medscimonit-23-1583]\]. It is able to promote tumor invasion and metastasis in several types of tumors \[[@b20-medscimonit-23-1583]--[@b22-medscimonit-23-1583]\]. However, details of ezrin-cortactin regulation, especially their potential function in EMT of breast cancer, have not yet been revealed.

Bioinformatic analysis suggests that ezrin and cortactin may be closely related to EMT. Both ezrin and cortactin are closely related to cell mobility, an important factor in the EMT process. Recent research has explored the regulatory effects of ezrin on EMT in cervical cancer and lung cancer \[[@b23-medscimonit-23-1583],[@b24-medscimonit-23-1583]\]. The interaction between ezrin and cortactin might promote cancer cell metastasis \[[@b25-medscimonit-23-1583]\]. The present work aimed to delineate the functional role and regulation of ezrin and cortactin during EMT of breast cancer. The interactive mechanisms between these 2 proteins were also investigated.

Material and Methods
====================

Cell lines and culture
----------------------

Human breast cancer cell lines (MDA-MB-231, MCF-7, and ZR-75-1) were purchased from ATCC (Manassas, VA, USA) and cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin, and 1% streptomycin. The cell line SUM1315 was kindly provided by Stephen Ethier (University of Michigan). The MDA-MB-231br cell line was established in a previous study \[[@b10-medscimonit-23-1583]\]. All cells were incubated at 37°C in a humidified chamber supplemented with 5% CO~2~.

Two-dimensional electrophoresis (2-DE) and mass spectrometry
------------------------------------------------------------

Two-dimensional electrophoresis analysis and protein identification by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) mass spectrometry was performed as described previously \[[@b26-medscimonit-23-1583]\]. Additional materials and methodologies are described in detail in the supporting materials and methods.

Plasmid construction and lentivirus packaging
---------------------------------------------

Vectors for EZR (ezrin) knockdown (shEZR) or negative controls (NC) were cloned in PGLV3-h1-GFP-puro. Vectors for EZR overexpression or encoding a scrambled sequence (SCR) (GenePharma, Shanghai, China) were similarly cloned in pGLV5-h1-GFP-puro. All vectors were transfected into lentivirus packaging cells. Four shRNA plasmids were constructed against different EZR targets, including a negative control sequence.

1.  sh1: 5′-GGAGTGAAATCAGGAACATCT-3′

2.  sh2: 5′-GGACCCACAATGACATCATCC-3′

3.  sh3: 5′-GCAACCATGAGTTGTATATGC-3′

4.  sh4: 5′-GCAATGAGGAGAAGCGCATCA-3′

5.  NC: 5′-TTCTCCGAACGTGTCACGT-3′

All plasmids were verified by sequencing (GenePharma, Shanghai, China). Retrovirus packaging and infection was conducted according to the manufacturer's instructions. Stable pooled populations of breast cancer cells were selected in puromycin (3 μg/ml) containing medium for 2 weeks. For knockdown analysis, 2 constructs (sh1 and sh2) with ≥80% knockdown efficiency were used for further studies.

siRNA design and transfection
-----------------------------

The siRNA (5′-GCUGAGGGAGAAUGUCUUUTT-3′) used for downregulation of cortactin as well as the negative control siRNA (5′-UUCUCCGAACGUGUCACGUdTdT-3′) were obtained from GenePharma, Shanghai, China. Transient transfection of the siRNA was performed using Lipofectamine 2000 according to the manufacturer's instructions.

Western blot analysis
---------------------

Cells were harvested using the total protein extraction kit (KeyGEN BioTECH, Nanjing, China). Samples were incubated for 0.5 h on ice with agitation and then centrifuged at 14 000×*g* for 15 min. Protein concentrations were determined using the bicinchoninic acid (BCA) protein assay kit (Pierce). Protein samples were subjected to electrophoresis on SDS-polyacrylamide gradient gels, transferred to a PVDF membrane, and blocked in 5% non-fat milk in TBST (phosphorylated proteins were blocked in 5% BSA in TBST) for 2 h at room temperature. Blots were incubated with primary antibodies to the following proteins: ezrin (Abcam), cortactin (Abcam), E-cadherin (CST), α-SMA (Abcam), Slug (CST), Snail (Abcam), Twist (Abcam), Twist2 (Abcam), phosphorylated ezrin at Y-567 (CST), and GAPDH (Beyotime). GAPDH was used on the same membrane as a loading control. The signal was detected after incubation with anti-rabbit or anti-mouse IgG secondary antibody (Bioworld) coupled to peroxidase, using ECL (Millipore). Protein expression levels were evaluated by densitometric analysis.

Real-time reverse transcription PCR analysis
--------------------------------------------

Total RNA was extracted using Trizol total RNA isolation reagent (TaKaRa), and cDNA was synthesized using PrimeScript RT Reagent (TaKaRa) according to the manufacturer's instructions. Specific primers from Invitrogen (Shanghai, China) were used for transcript detection. All PCR reactions were performed with SYBR Green I (Roche) for detection. Real-time quantitative PCR was performed on StepOne Plus Real-Time PCR system (Applied Biosystems, USA). The following PCR primers were used:

1.  ezrin forward, 5′-ACCAATCAATGTCCGATTACC-3′

2.  ezrin reverse, 5′-GCCGATAGTCTTTACCACCTGA-3′

3.  GAPDH forward, 5′-GCTGCGAAGTGGAAACCATC-3′

4.  GAPDH reverse, 5′-CCTCCTTCTGCACACATTTGAA-3′

The average of 3 independent analyses for each gene and sample was calculated and normalized to the endogenous reference control gene GAPDH.

Matrigel invasion assay and migration assay
-------------------------------------------

Matrigel was purchased from BD Biosciences and stored at −20°C. After thawing at 4°C overnight, the Matrigel was diluted in serum-free DMEM. For carrying out the invasion assay, 50 μl of the suspension was evenly inoculated onto the upper chamber of a Transwell membrane (8 μm pore size) and allowed to form a gel at 37°C. Cells (5×10^4^) were overlaid with 200 μl of serum-free DMEM on Matrigel-coated Transwell membranes with 0.5 ml of complete medium in the lower chamber. After incubating for 48 h at 37°C in a humidified atmosphere of 5% CO~2~, the cells were fixed and stained with 0.1% crystal violet solution for 20 min, and the chamber was washed 3 times with phosphate-buffered saline (PBS). Non-invading cells on the top of the membrane were removed using cotton wool. Invading cells were counted under a microscope. In each Matrigel invasion experiment, 3 independent replicates were performed.

To carry out the migration assay, cells (3×10^4^) were overlaid with 200 μl serum-free DMEM on Transwell membranes without Matrigel-coating, and incubated for 16 h. The remainder of this assay was performed as described in the invasion assay.

Growth curve by CCK8 assay
--------------------------

Cells (2×10^3^) were grown in microtiter plates in a final volume of 100 μl of complete medium per well, at 37°C and 5% CO~2~. The growth curve was carried out over a period of 6 days. After the incubation period, 10 μl of the CCK8 (Dojindo) labeling reagent (0.5 mg/ml) was added to each well. The cells were subsequently analyzed by enzyme-labeled meter (Tecan) to measure their absorption at 450 nm. Each treatment was performed in triplicate.

Colony formation assay
----------------------

Cells (5×10^2^) were plated in a 6-well plate in complete medium. After incubation for 10--14 days, when the colonies were visible by eye, the culture was terminated by removing the medium and washing the cells twice with PBS. The colonies were fixed with 95% ethanol for 100 s, then dried and stained with 0.1% crystal violet solution for 10 min, and washed with PBS. Images were obtained and the number of colonies containing more than 50 cells was counted. Each treatment was performed in triplicate.

Tissue microarray (TMA) and immunohistochemistry (IHC)
------------------------------------------------------

TMAs were purchased from BioMax (USA). Sections were arranged in duplicate cores per case. TMAs were treated with xylene, then 100% ethanol, and then decreasing concentrations of ethanol. After antigen retrieval, they were blocked and stained with antibodies against ezrin or cortactin, followed by secondary antibody incubation and the standard avidin biotinylated peroxidase complex method. Hematoxylin was used for counterstaining and images were taken with an upright microscope Nikon system (Nikon, JAPAN).

A modified Histo-score was used to perform IHC scoring, which was assessed by both intensity of staining and percentage of positive area. The extent of the positive area was scored on a scale of 0--4 as follows: 0, 0%; 1, 1--10%; 2, 11--50%; 3, 51--80%; and 4, \>80%. The final staining score from 0--12 for ezrin and cortactin was the product of the staining intensity and positive area scores. A score of 0--7 indicated low expression and between 8--12 indicated high expression in ezrin. In cortactin, scores of 0--3, 4--7, and 8--12 were considered indicative of low, moderate, and high expression, respectively.

Co-immunoprecipitation (Co-IP)
------------------------------

Extract from 1×10^7^ cells was obtained. The protein was immunoprecipitated using anti-ezrin or rabbit IgG control according to the manufacturer's instructions, and then subjected to immunoblotting.

Statistical analysis
--------------------

Statistical significance between and within groups in the Transwell and proliferation assays was assessed by *t* test or one-way ANOVA, using SPSS 20.0. Statistical significance of differences between ezrin expression and other indexes in the TMA was determined by a non-parametric test, chi-square test, or Fisher exact test. For all tests, results at p values \<0.05 were taken to represent a statistically significant difference.

Results
=======

MDA-MB-231br has a strong EMT-like process, including invasion and migration
----------------------------------------------------------------------------

A Transwell assay was performed to measure the invasive and migratory ability of MDA-MB-231 and MDA-MB-231br cells. MDA-MB-231br cells had a significantly increased ability to migrate and invade compared to that of MDA-MB-231 cells ([Figure 1A](#f1-medscimonit-23-1583){ref-type="fig"}). Western blot analysis indicated that the level of E-cadherin expression was decreased in MDA-MB-231br compared to MDA-MB-231, while the expression pattern of vimentin was the inverse ([Figure 1B](#f1-medscimonit-23-1583){ref-type="fig"}).

Identification of differentially expressed proteins between MDA-MB-231 and MDA-MB-231br
---------------------------------------------------------------------------------------

Two-dimensional gel electrophoresis and mass spectrometry identified 81 differentially expressed proteins between MDA-MB-231 and MDA-MB-231br ([Supplementary Figure 1](#s1-medscimonit-23-1583){ref-type="supplementary-material"}, [Supplementary Table 1](#s2-medscimonit-23-1583){ref-type="supplementary-material"}). From these proteins, ezrin, cortactin, hsp27, lasp2, and annexin II were selected ([Figure 1C](#f1-medscimonit-23-1583){ref-type="fig"}) for validation by Western blot ([Figure 1B](#f1-medscimonit-23-1583){ref-type="fig"}). In MDA-MB-231, the level of ezrin expression decreased and cortactin expression increased compared to that in MDA-MB-231br ([Figure 1B, 1C](#f1-medscimonit-23-1583){ref-type="fig"}). However, the phosphorylation of ezrin at position Y-567 increased in MDA-MB-231br compared to that in MDA-MB-231 ([Figure 1B](#f1-medscimonit-23-1583){ref-type="fig"}).

Knockdown of ezrin changes cellular morphology, and membranous marker and EMT indicator expression
--------------------------------------------------------------------------------------------------

MDA-MB-231 and SUM1315 breast cancer cells, which have high invasive potential and highly-expressed ezrin, were used for the next study. Knockdown efficiency of ezrin was confirmed by real-time PCR and immunoblotting ([Figure 2A](#f2-medscimonit-23-1583){ref-type="fig"}). The phosphorylation of ezrin at position Y-567 was also decreased in ezrin knockdown cells ([Figure 2A](#f2-medscimonit-23-1583){ref-type="fig"}). Alternatively, MCF-7 and ZR-75-1 breast cancer cells, which rarely metastasize \[[@b27-medscimonit-23-1583]\], were transfected with an ezrin overexpression vector. In the cells overexpressing ezrin, marked upregulation of ezrin was confirmed by real-time PCR and immunoblotting ([Figure 2B](#f2-medscimonit-23-1583){ref-type="fig"}).

The expression levels of an epithelial marker (E-cadherin) and a mesenchymal marker (α-SMA) were examined by immunoblotting. The expression level of E-cadherin was significantly increased, whereas that of α-SMA was decreased in ezrin-knockdown cells compared to that in control cells ([Figure 2C](#f2-medscimonit-23-1583){ref-type="fig"}). In MCF-7 and ZR-75-1 cell lines, overexpressing ezrin had no effect on the expression of E-cadherin and α-SMA ([Figure 2D](#f2-medscimonit-23-1583){ref-type="fig"}). The expression levels of Slug, Snail, Twist, and Twist2, which are key transcription factors that promote EMT, were also determined by immunoblotting. Significantly reduced expression of Snail, Twist, and Twist2 was observed in ezrin-knockdown cells compared with that in the control cells ([Figure 2C](#f2-medscimonit-23-1583){ref-type="fig"}).

Ezrin knockdown reduced the migration and invasion of breast cancer cells
-------------------------------------------------------------------------

Ezrin knockdown in MDA-MB-231 cells changed the cell morphology remarkably ([Figure 3A](#f3-medscimonit-23-1583){ref-type="fig"}). MDA-MB-231 cells are widely accepted as having a mesenchymal phenotype, while ezrin-knockdown cells presented an epithelial phenotype ([Figure 3A](#f3-medscimonit-23-1583){ref-type="fig"}). However, the shape of SUM1315 after ezrin knockdown did not visibly change ([Figure 3B](#f3-medscimonit-23-1583){ref-type="fig"}). Increased motility and invasion of breast cancer cells are key steps in the EMT process. Ezrin knockdown was associated with significantly reduced migratory and invasive ability in MDA-MB-231 and SUM1315 cells ([Figure 3C, 3D](#f3-medscimonit-23-1583){ref-type="fig"}).

In general, cells with high invasive ability had enhanced ability for proliferation. However, the CCK8 assay and colony formation assay suggested that decreased expression of ezrin in breast cancer cells had no effect on cell proliferation ([Figure 4A, 4B](#f4-medscimonit-23-1583){ref-type="fig"}).

Ezrin is positively correlated with cortactin in breast cancer
--------------------------------------------------------------

The expression of cortactin decreased with the reduction of ezrin expression ([Figure 5A](#f5-medscimonit-23-1583){ref-type="fig"}). Co-IP analysis suggested a connection between the expression of ezrin and cortactin in SUM1315 cells ([Figure 5B](#f5-medscimonit-23-1583){ref-type="fig"}), but not in MDA-MB-231 cells (data not shown). The expression of cortactin was knocked down and confirmed by immunoblotting ([Figure 5C](#f5-medscimonit-23-1583){ref-type="fig"}). In cortactin-knockdown cells, the expression of ezrin and p-ezrin did not change obviously. In cortactin-knockdown cells, the level of E-cadherin expression was significantly increased, whereas that of α-SMA was decreased ([Figure 5C](#f5-medscimonit-23-1583){ref-type="fig"}).

In clinical breast cancer tissues, a significant positive association was observed between ezrin and cortactin expression ([Table 1](#t1-medscimonit-23-1583){ref-type="table"}, [Figure 5D](#f5-medscimonit-23-1583){ref-type="fig"}).

Discussion
==========

In this study, evidence for MDA-MB-231br undergoing an EMT-like process included increased spindle morphology, stronger invasive ability, and decreased expression of E-cadherin. Eighty-one differentially expressed proteins were identified following proteomic analysis comparing MDA-MB-231br and MDA-MB-231 cells. Along with protein-level changes in expression of a group of classic EMT markers, ezrin and cortactin were significantly regulated. The changes observed in these cells may be attributed to a response to an EMT-inducing microenvironmental signal. We hypothesized that these proteins included novel protein signatures of EMT, and demonstrated the function of ezrin and cortactin in breast cancer. In MDA-MB-231br cells with an EMT-like phenotype, the expression of ezrin decreased, whereas the phosphorylation of ezrin at position Y-567 changed in the opposite way. Ezrin and phosphorylated ezrin were decreased synchronously, and cell morphology varied from spindle to oval. Reduced ezrin expression reversed the EMT process through changes in the expression of EMT markers and downregulation of transcription factors. Conversely, overexpression of ezrin had no obvious effect on the EMT process. This implies that ezrin-knockdown could reverse the EMT cascade, which might affect its phosphorylation state. The phosphorylation state of ezrin might be more important than its expression level. The role of ezrin expression in metastasis has been demonstrated in animal models, while no change has been observed in primary tumor growth rate \[[@b17-medscimonit-23-1583]\]. The expression level of ezrin is significantly higher in lymphatic metastases than in primary breast cancer tissues \[[@b28-medscimonit-23-1583]\]. Cytoplasmic ezrin is regarded as a single characteristic marker in breast cancer \[[@b29-medscimonit-23-1583]\]. The phosphorylation of ezrin at position Y-567 disrupts its amino- and carboxyl-terminal associations, and thus plays a key role in modulating the conformation and function of ERM proteins \[[@b30-medscimonit-23-1583]\] It is reported that the phosphorylation of ezrin regulates invasion and metastasis of breast cancer cells \[[@b31-medscimonit-23-1583]\].

In the present study, increased expression of cortactin was observed in MDA-MB-231br cells with increased expression of phosphorylated ezrin. Conversely, decreased phosphorylation of ezrin reduced the expression of cortactin. Cortactin knockdown had no effect on the expression of ezrin and its phosphorylation. Ezrin also acts as a membrane-cytoskeleton crosslinker, which can affect structural modifications under the control of several upstream or downstream regulators. Paladin and S100P are known to form large protein complexes with ezrin \[[@b32-medscimonit-23-1583],[@b33-medscimonit-23-1583]\], and cortactin is thought to cooperate with ezrin in tumor progression \[[@b25-medscimonit-23-1583]\]. Cortactin, which is localized to cortical actin structures, not only plays a crucial role as a regulator of actin cytoskeletal dynamics, but also acts as a key player in aggressive cancers \[[@b31-medscimonit-23-1583]\].

Our results elucidate the interaction between ezrin and cortactin. The association between ezrin and cortactin was explored in SUM1315 cells. There was no observed co-precipitation between ezrin and cortactin in the MDA-MB-231 cell line, which might be because ezrin expression was not high enough to show this change in these cells. The positive correlation between these 2 proteins was demonstrated in the breast cancer tissue microarray.

Conclusions
===========

In summary, ezrin, based mainly on its phosphorylation state, appears to interact with cortactin to promote the EMT process in breast cancer. Ezrin and cortactin may therefore be potential therapeutic targets and prognostic indicators of breast cancer.

Supplementary Files
===================

###### 

Two-dimensional gel electrophoresis(2-DE) analysis of proteins extracted from different cell lines species: (**A**) MDA-MB-231; (**B**) MDA-MB-231br.

###### 

Identification of up- and down-regulated proteins in MDA-MB-231br cells compared to MDA-MB-231 cells.

  No.   Accession No   AC            Theor. mol   Measured    Sequence   Peptides a   Fold chang   Student T
  ----- -------------- ------------- ------------ ----------- ---------- ------------ ------------ -----------
  1     gi\|7706425    LSM8          10.4/4.34    11.5/4.11   0.82       4            0            6.9501
  2     gi\|38511503   LOC400581     13.2/7.88    14.4/7.73   0.57       11           0            3.32884
  3     gi\|5453740    MRCL3         19.8/4.67    21.0/4.46   0.63       12           0            22.6371
  4     gi\|11957604   GLO1          21.0/5.12    23.1/5.38   0.29       19           0.1458951    5.8117
  5     gi\|11958606   PRDX6         22.8/5.98    20.6/5.65   0.56       14           0.3751647    3.13876
  6     gi\|4504517    HSPB1         22.8/5.98    21.5/6.26   0.49       11           1.7085594    6.85507
  7     gi\|4506195    PSMB2         23.0/6.51    17.7/5.28   0.37       11           0.5424243    3.47661
  8     gi\|11962339   RANBP1        23.5/5.19    26.9/4.31   0.42       16           0.5717237    5.58285
  9     gi\|31645      GAPDH         31.7/7.15    35.9/4.79   0.57       27           2.3023371    3.26693
  10    gi\|914957     GRB2          25.3/5.89    28.4/5.48   0.51       13           ND           5.22913
  11    gi\|20149675   TUBB          26.8/5.15    31.2/4.82   0.46       12           3.1617546    9.1124
  12    gi\|16357477   CDC34         26.9/4.41    28.0/4.2    0.32       9            0.3679367    3.0581
  13    gi\|44979607   IMPDH2        27.3/5.84    29.4/6.1    0.6        9            0.4022986    5.13788
  14    gi\|48145973   NDUFV2        27.7/8.22    26.3/8.67   0.33       8            0.3474179    2.92579
  15    gi\|19298714   PGLS          27.8/5.7     25.6/5.37   0.37       9            0.4460076    3.16474
  16    gi\|4758484    GSTO1         27.8/6.23    26.5/6.51   0.48       15           0.2449022    4.34464
  17    gi\|19378506   PSPHL;ACTG1   28.5/5.2     23.2/3.97   0.45       12           0.4615403    3.08667
  18    gi\|17402904   EXOSC6        28.5/6.06    31.9/5.18   0.3        12           0.2836561    4.7922
  19    gi\|62897753   hCG_2015269   29.0/6.67    26.8/6.34   0.79       19           0.3179457    3.64943
  20    gi\|19298714   ERP29         29.0/6.77    27.7/7.05   0.39       10           0.4765053    3.36723
  21    gi\|4826659    CAPZB         29.6/6.45    24.3/5.22   0.64       26           0.4184514    2.90687
  22    gi\|19438056   LASP1         30.1/6.61    33.5/5.73   0.58       8            0.2488259    5.5738
  23    gi\|22652991   TPI1          31.1/5.65    35.3/3.29   0.56       14           0.4883441    7.47102
  24    gi\|21361454   PYCR2         34.4/8.48    37.5/8.07   0.54       24           0.3732397    5.90677
  25    gi\|18906542   HNRPC         32.4/4.94    36.8/4.61   0.53       20           0.5408701    6.3532
  26    gi\|12803709   CK14          32.4/4.97    33.5/4.76   0.33       17           0.4598442    3.63144
  27    gi\|11056044   PPA1          33.1/5.54    35.3/5.8    0.5        17           0.4610924    2.78434
  28    gi\|5174447    TST           33.6/6.77    32.3/7.22   0.37       14           0.4618559    2.78215
  29    gi\|10437514   SUHW4         35.1/8.68    32.9/8.35   0.42       14           ND           11.2023
  30    gi\|11962858   DNAH3         473.8/6.04   472.5/6.    0.27       14           0.3843506    2.9416
  31    gi\|4826643    ANXA3         36.5/5.63    31.2/4.4    0.56       23           0.5335611    5.71278
  32    gi\|19438981   CNN3          36.6/5.69    35.2/6.14   0.49       17           3.3243097    7.20813
  33    gi\|2119276    TUBB          48.1/4.7     45.9/4.37   0.25       14           1.8615634    3.20717
  34    gi\|73976124   HNRPA2B1      37.5/8.97    36.1/9.25   0.46       12           2.5249017    6.79964
  35    gi\|17402893   PSAT1         40.8/7.56    35.5/6.33   0.55       26           1.6654277    3.88025
  36    gi\|19437787   ARFIP2        37.9/5.72    41.4/4.84   0.38       12           1.7420536    2.80585
  37    gi\|22104024   PPP1CB        38.0/5.84    42.2/3.48   0.22       8            0.3430111    4.85873
  38    gi\|11960877   PPP1CB        38.0/5.84    41.1/5.43   0.4        23           0.4678427    3.05192
  39    gi\|6912280    AHSA1         38.4/5.41    33.1/4.18   0.19       8            4.3644831    5.00035
  40    gi\|7305503    STOML2        38.6/6.88    42.1/6      0.52       18           0.2565899    4.2268
  41    gi\|11959799   ANXA2         38.8/7.57    36.6/7.24   0.6        20           2.2824303    4.00567
  42    gi\|4506127    PRPS1         35.3/6.51    34.0/6.79   0.47       21           1.9003629    5.43115
  43    gi\|93277122   BUB3          32.1/8.4     26.8/7.17   0.43       15           3.4236124    10.8789
  44    gi\|4503895    GALK1         42.7/6.04    46.9/3.68   0.35       17           6.5938433    3.2962
  45    gi\|11960222   CKB           42.9/5.34    46.0/4.93   0.45       15           2.6276618    3.86433
  46    gi\|15825518   SERPINB7      43.2/6.34    47.6/6.01   0.34       12           0.2890603    11.6406
  47    gi\|19438418   HSPA8         71.1/5.37    72.2/5.16   0.24       14           1.8781699    3.44432
  48    gi\|5174529    MAT2A         44.0/6.02    46.1/6.28   0.32       14           0.3873342    3.38533
  49    gi\|19378506   ACTB          45.5/5.82    44.1/6.27   0.27       7            2.5188648    4.86371
  50    gi\|5729991    PSMC4         47.5/5.09    45.2/4.76   0.45       19           2.9751505    7.05399
  51    gi\|20328236   ENO1          47.5/7.01    50.9/6.13   0.33       14           0.4514455    5.84011
  52    gi\|20328236   ENO1          47.5/7.01    51.7/4.65   0.38       14           2.1757631    2.78494
  53    gi\|28872725   PSMD11        47.8/6.08    50.9/5.67   0.25       12           2.2969517    4.67432
  54    gi\|35071      MTHFD2        38.0/8.86    42.4/8.53   0.02       11           3.0997653    3.33509
  55    gi\|21623852   PSMC3         49.5/5.13    48.1/5.58   0.22       19           3.0467243    3.32863
  56    gi\|21623852   PSMC3         49.5/5.13    47.3/4.8    0.47       24           1.9425454    4.2506
  57    gi\|20328236   ENO1          47.5/7.01    46.2/7.29   0.63       29           1.5667183    4.24397
  58    gi\|16507237   VIM           49.7/5.19    44.4/3.96   0.4        20           2.3352391    3.4501
  59    gi\|14043072   HNRPA2B1      37.5/8.97    40.9/8.09   0.5        25           2.118541     2.97696
  60    gi\|11960877   TUBB2A        50.3/4.78    54.5/2.42   0.42       16           2.5802857    3.58321
  61    gi\|28948869   VIL2          69.5/5.94    72.6/5.53   0.39       18           2.6162373    3.95062
  62    gi\|11960683   GDI2          51.1/6.11    55.5/5.78   0.38       16           4.2414899    8.61448
  63    gi\|38569475   MTX1          51.7/9.8     46.4/8.57   0.36       14           ND           10.9218
  64    gi\|449441     UGP2          55.8/7.69    59.2/6.81   0.39       24           3.9755451    4.09809
  65    gi\|48255968   UGP2          55.8/7.69    60.0/5.33   0.52       27           2.5612084    6.32672
  66    gi\|66933016   IMPDH2        56.2/6.44    59.4/6.03   0.42       20           0.4828852    10.5545
  67    gi\|11961763   CCT2          57.8/6.01    62.2/5.68   0.39       15           4.6695429    4.39079
  68    gi\|4557976    ALDOA         39.9/8.3     41.0/8.09   0.47       20           2.0385729    3.2317
  69    gi\|22104614   CCT5          60.1/5.45    62.2/5.71   0.53       26           2.3538723    4.52031
  70    gi\|20151189   GLUD1         61.7/7.66    60.3/8.11   0.33       13           0.3442582    9.36776
  71    gi\|19437434   HSPA5         72.5/5.07    70.3/4.74   0.71       24           5.0750799    3.96361
  72    gi\|11463825   STIP1         63.2/6.4     66.7/5.52   0.51       37           3.6341375    2.79519
  73    gi\|16915936   MGAT4B        65.1/8.38    69.3/6.02   0.29       10           2.8100682    3.95651
  74    gi\|9910460    ZNF714        69.3/9.16    72.4/8.75   0.3        9            2.8886894    3.2727
  75    gi\|182087     CTTN          61.9/5.28    66.3/4.95   0.32       21           7.0312418    6.24639
  76    gi\|13676857   HSPA2         70.3/5.56    68.9/6.01   0.27       15           2.6325321    3.0962
  77    gi\|13676857   HSPA2         70.3/5.56    68.1/5.23   0.44       29           ND           37.1179
  78    gi\|1017722    ZNF85         70.9/9.48    69.6/9.76   0.26       14           3.6214245    3.22252
  79    gi\|57014047   LMNA          70.9/8.55    65.6/7.32   0.5        31           5.398146     3.33403
  80    gi\|29645294   SNIP          112.7/9.32   116.1/8.    0.24       16           2.8558356    3.07003
  81    gi\|542991     ROR2          80.8/7.3     85.1/4.94   0.51       12           ND           11.6562

VIL2 -- Chain A, structure of the active ferm domain of ezrin; CTTN -- cortactin.
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![MDA-MB-231br cells are strongly capable of invasion and migration. (**A**) The novel human breast cancer cell line MDA-MB-231br isolated from the metastatic mouse model and MDA-MB-231 were stimulated to migrate and invade in Transwell chambers. Representative photographs (**upper panel**) and quantification (**lower panel**) are shown. Columns: average of 3 independent experiments, \* *p*\<0.05. Magnification ×100. (**B**) EMT markers, including E-cadherin, vimentin, ezrin, cortactin, annexin II, hsp27, lasp2, and ezrin-T567 were differently expressed in MDA-MB-231 and MDA-MB-231br cell lines, according to Western blotting analysis with GAPDH as the internal control. (**C**) Differentially expressed proteins were identified in MDA-MB-231 and MDA-MB-231br cell lines by two-dimensional electrophoresis (2-DE) and mass spectrometry.](medscimonit-23-1583-g001){#f1-medscimonit-23-1583}

![Downregulation of ezrin reverses EMT in MDA-MB-231 and SUM1315 cells. (**A**) The expression levels of ezrin were verified in MDA-MB-231 and SUM1315 after transfection of shRNA against ezrin or upon ezrin overexpression, by Western blot and qRT-PCR, respectively. \*\* *p*\<0.01, \*\*\* *p*\<0.001. The phosphorylation of ezrin at position Y-567 was decreased with decreased ezrin expression. (**B**) The expression of ezrin was verified in MCF-7 and ZR-75-1 cells after ezrin overexpression, by Western blots and qRT-PCR, respectively. \*\* *p*\<0.01, \* *p*\<0.05. (**C**) Western blot analysis revealed that knockdown of ezrin resulted in increased expression of an epithelial marker (E-cadherin) and decreased expression of a mesenchymal marker (α-SMA) in MDA-MB-231 and SUM1315 cells. Snail, Twist, and Twist2, which are key transcription factors that promote EMT, were significantly decreased in ezrin-downregulated MDA-MB-231 and SUM1315 cells. (**D**) The overexpression of ezrin did not alter the expression of E-cadherin and α-SMA in MCF-7 and ZR-75-1 cells.](medscimonit-23-1583-g002){#f2-medscimonit-23-1583}

![Knockdown of ezrin changes the phenotype and significantly decreases the migratory and invasive potential of breast cancer cells. (**A**) The phenotype of MDA-MB-231 cells after ezrin knockdown changed from spindle to oval. Magnification ×100. (**B**) The shape of SUM1315 after ezrin knockdown had no visible change. Magnification ×100. (**C, D**) MDA-MB-231 and SUM1315 cells transfected with shRNA against ezrin were subsequently subjected to Transwell migration assay and Matrigel invasion assay. Representative photographs (**upper panel**) and quantification (**lower panel**) are shown. Columns: average of 3 independent experiments, \* *p*\<0.05, \*\* *p*\<0.01. Magnification ×100.](medscimonit-23-1583-g003){#f3-medscimonit-23-1583}

![Effect of ezrin on proliferation and growth of breast cancer cell lines. (**A**) The growth of MDA-MB-231 and SUM1315 cells cultured for 6 days was measured by use of a cell counting kit (CCK-8) assay. There was no obvious change between MDA-MB-231 or SUM1315 and the corresponding control cells with regards to the rate of proliferation. (**B**) The colony formation assay was also performed to measure the growth of cells. There was also no obvious change between MDA-MB-231 or SUM1315 cells compared to the rate of proliferation of their respective control cells.](medscimonit-23-1583-g004){#f4-medscimonit-23-1583}

![Ezrin and cortactin express a similar pattern in breast cancers. (**A**) In MDA-MB-231 or SUM1315 cells, the reduction in ezrin expression occurred alongside the reduction in cortactin. (**B**) Co-IP analysis suggested a connection between ezrin and cortactin in SUM-1315 cells. (**C**) The expression and phosphorylation of ezrin did not change in MDA-MB-231 or SUM1315 cells transfected with siRNA against cortactin. Knockdown of cortactin resulted in increased expression of E-cadherin and decreased expression α-SMA in SUM1315 cells. (**D**) Immunohistochemistry revealed significant correlations between ezrin expression and cortactin expression. Magnification ×400.](medscimonit-23-1583-g005){#f5-medscimonit-23-1583}

###### 

The association of ezrin with cortactin expression and clinicopathologic features of breast cancer.

  Clinicopathologic parameters   Number of case   Ezrin expression   P-value   
  ------------------------------ ---------------- ------------------ --------- -----------
  Age (years)                                                                  0.992
   ≤55                           55               38                 17        
   \>55                          13               9                  4         
  Grade                                                                        0.325
   I                             3                1                  2         
   II                            37               20                 17        
   III                           9                6                  3         
   Unclear                       19               13                 6         
  TNM stage                                                                    0.356
   I+II                          52               29                 23        
   III+IV                        16               11                 5         
  Cortactin                                                                    **0.001**
   Low                           4                4                  0         
   Middle                        11               11                 0         
   High                          53               25                 28        

TNM classification according to the International Union Against Cancer criteria.
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